Human Irisin Concentration in Sarcopenia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01874912

Enrollment

406

Registered

2013-06-11

Start date

2009-11-30

Completion date

2011-04-30

Last updated

2013-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, the researches investigated whether serum irisin levels are decreased in patients with sarcopenia compared with control subjects with normal muscle mass, and assessed the association between serum irisin levels and various metabolic parameters.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* 20\<age\<80 * apparently healthy subjects

Exclusion criteria

* a history of cardiovascular disease * diabetes * stage 2 hypertension * malignancy * severe renal or hepatic disease

Design outcomes

Primary

Measure	Time frame
Serum concentration of irisin in the subjects with sarcopenia	12 week

Secondary

Measure	Time frame
The relationship of serum irisin levels with lipid profiles	12 week
The relationship of serum irisin levels with skeletal muscle mass index	12 wks

Countries

South Korea

Outcome results